Response to the letter "The effect of Alzheimer's disease comorbidity in tap test response in idiopathic normal pressure hydrocephalus?" from Dr. Onder et al.

Evaluation of biopsy specimens and amyloid imaging may be preferable to confirm AD comorbidity in iNPH more reliable than CSF biomarkers. However, because these features are the characteristics of AD compared to iNPH, we might not be able to simply use them to examine the differences between iNPH patients with and without the comorbidity of AD. The authors of the letter suggest that the clinical and neuroimaging signs of AD should be used to support AD comorbidity in addition to CSF biomarkers. [Extracted from the article]